RE: Odx27 May 2020 17:03
Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing, notes the recent rise in the Company's share price and confirms that it is not aware of any material reason for the significant increase.
As previously announced the Company continues to work with its partner Mologic Ltd with regards its first generation ELISA antibody test for COVID-19 and also with the UK Rapid Test Consortium, which is jointly developing, and will manufacture, a Point-of-Care COVID-19 lateral flow antibody test.
In respect of both these opportunities the Company will keep the market informed as matters develop.